PharmaFocus Today – Page 5 – media

Layoffs, Business Transfer

Recently, foreign media reported that Philips Wellcome has notified its suppliers that it plans to outsource the manufacturing operations of its factories in Murrysville and New Kensington, Pennsylvania to Thailand. It is reported that this is based on a letter sent by Philips subsidiary to suppliers in June, stating that contractor manufacturer Kimball Electronics will take over this work at its Thailand factory in the next two years. The Pittsburgh Post reported that this move will result in the reduction of hundreds of job positions. It is understood that the two manufacturing plants in Pennsylvania are part of Philips Wellcome’s operations and are subject to a consent order from the FDA and the US Department of Justice, which involves the company’s large-scale recall of continuous positive airway pressure (CPAP) and bi level positive airway pressure (BiPAP) ventilators in Class I. Philips stated in a statement to the Pittsburgh Post that ...
- Source: drugdu
- 42
- November 2, 2024
Mesenchymal stromal cells (non stem cells) have been approved by the FDA for clinical trials in the treatment of acute ischemic stroke

The world’s first allogeneic adipose derived mesenchymal stromal cells (AD MSCs) drug (NR-20201) developed by Tianshi Pharmaceutical Group Co., Ltd. for the treatment of acute ischemic stroke received clinical trial approval from the US Food and Drug Administration (FDA) on October 26, 2024. It is reported that in the process of developing NR-20201, the company used artificial intelligence to analyze single-cell transcriptomics, cell life trajectories, and fate outcomes [1,2], confirming that the AD MSCs produced by Tasly’s standard preparation process are mesenchymal stromal cells rather than mesenchymal stem cells. Based on the difference between stromal cells and stem cells, this product has unique identification criteria and a mechanism of action different from stem cells. This product selects a suitable treatment time window based on the patient’s condition, promoting effective homing of cells after intravenous infusion. After cell homing, it works synergistically with endothelial cells to activate vascular regeneration and functional ...
- Source: drugdu
- 41
- November 2, 2024
AI+Gene Therapy | Dyno partners with Roche, with a prepayment of $50 million and a total value exceeding $1 billion

On October 24, 2024, Dyno Therapeutics, a gene technology company that utilizes artificial intelligence for in vivo gene delivery, announced its second research collaboration with Roche to jointly develop the next generation of adeno-associated virus (AAV) vectors for gene therapy targeting neurological diseases.Dyno and Roche previously announced a research collaboration and licensing agreement in October 2020 for neurological disorders and liver targeted therapies. According to this new collaboration agreement, Dyno Therapeutics will provide Roche with more opportunities to utilize the company’s leading platform and sequence design technology in the field to achieve in vivo gene delivery. The existing gene therapies mainly use a small amount of naturally occurring AAV vectors, which have problems such as low delivery efficiency, pre-existing immunity, and manufacturability. To overcome these challenges, Dyno took the lead in applying artificial intelligence and high-throughput in vivo data acquisition technology to engineer the AAV virus capsid, in order to ...
- Source: drugdu
- 47
- November 1, 2024
The 3rd Analysis and Testing Summit Forum and Academic Annual Conference of the Journal of Analysis and Testing in 2024 grandly opened in Guangzhou

From September 21st to 25th, 2024, the “2024 Analysis and Testing Summit Forum and Annual Conference of Analysis and Testing Academic Newspaper” jointly organized by the Journal of Analysis and Testing, the Testing and Analysis Research Institute of Guangdong Academy of Sciences (Guangzhou Analysis and Testing Center, China), the China Association for Analysis and Testing, and the Guangdong Association for Analysis and Testing was held at the Nikko Hotel in Guangzhou. This forum focuses on innovation and development in the field of analysis and testing, attracting more than 1000 academicians, scholars, and business representatives from various cutting-edge fields such as environment and health, life analysis, food safety, new technologies, and scientific instrument development; By adopting a combination of online and offline modes, we have successfully attracted over 10000 online viewers, breaking down geographical boundaries and expanding our audience base. On the morning of the 23rd, the forum was officially opened. ...
- Source: drugdu
- 67
- November 1, 2024
Total investment is 500 million yuan! The first integrated intelligent factory project for synthetic biology CDMO full process in Jiangsu Province has been launched

On the morning of October 22nd, Fenghuang Town successfully signed a contract with Suzhou Womei Biotechnology Co., Ltd. for the “Womei Biosynthetic CDMO Factory” project, which is the first project to settle in Feixiang Pharmaceutical Industrial Park since its approval. Teng Xiaonuo, General Manager of Suzhou Womei Biotechnology Co., Ltd., Professor Ren Guobin, Vice Dean of the Research Institute of East China University of Science and Technology, Wang Weimin, Secretary of the Phoenix Town Party Committee, Tian Wenhua, Deputy Secretary of the Town Party Committee and Mayor, Ji Xiaoyang, Deputy Secretary of the Town Party Committee, and others participated in the signing. This project is based on leading process control and intelligent manufacturing technologies at home and abroad, and aims to establish a green intelligent factory that integrates consumables, process engineering, and equipment. It balances production efficiency and cost control, and strives to build a first-class synthetic biology CDMO industry ...
- Source: drugdu
- 47
- November 1, 2024
Determination to break up

The operations of Cinda, a star company in China’s biotech industry, in the past two days have finally made an investor who has firmly held Cinda shares for many years determined to break up: no longer obsessed with Cinda’s future, and resolutely clear all Cinda shares. The spin-off of Cinda’s subsidiaries and the founder’s “low-price” purchase of the subsidiary’s equity are still fermenting. The news was announced on Friday night. In the bull market where all industries have been rising for several weeks, Cinda fell 12.54% on Monday, and fell again on Tuesday after a conference call to explain the matter, closing down 4.01% on the day. On Wednesday, Cinda’s stock continued to fall, falling 4.85% in midday trading today. “It’s mainly because it’s a bull market now. If it were three months ago, it would have basically fallen by 30%.” An industry insider said. The market’s disappointment with Innovent ...
- Source: drugdu
- 47
- November 1, 2024
Million-RMB-worth CAR-T Drugs Miss Out on Health Insurance Negotiations for the Fourth Time

This morning, the much-anticipated on-site negotiations for the 2024 National Health Insurance Drug List adjustment concluded. According to First Financial News, CAR-T drugs have once again been absent from this round of negotiations, marking the fourth consecutive time they have not participated. “None of us appeared at the health insurance negotiation site,” a representative from a CAR-T company told First Financial News. The latest negotiations began on October 27, with 25 health insurance negotiation experts divided into five groups, negotiating and bidding for 162 types of drugs. The list of drugs under negotiation included commonly used medications for diabetes, hypertension, and infections, as well as medications for tumors and rare diseases. The final results of the on-site negotiations and bidding will be announced separately. Earlier, on August 27, the National Health Insurance Administration published a notice regarding the drug list adjustments for the 2024 National Basic Health Insurance, Work Injury ...
- Source: drugdu
- 56
- November 1, 2024
brain-computer interface only costs $5,000

In reality, the brain-computer interface is connected to your brain at one end, extracting your ideas from the dense and complex neuronal electrical signals, and connected to external devices such as computers or machinery at the other end, directly bypassing your body to turn ideas into control signals and further execute commands. It does not need to rely on the peripheral nerves and muscle systems of your limbs to directly establish direct information exchange between the brain center and external devices. Musk released a monkey for experiment in 2021. The monkey typed a line of words “I want to eat snacks” on the computer through mind operation. This is supported by brain-computer interface technology. The cochlear implant that helps the disabled to obtain sound is the most successful and most popular technology for brain-computer interface so far. Its principle is to convert sound signals into electrical signals and transmit them ...
- Source: drugdu
- 45
- November 1, 2024
the wind rises, accelerates, and accelerates again

The development story of tumor drugs is always so similar: the early stage may be endless suffering, but after countless failures and dashed hopes, once there is a breakthrough, the progress is often unexpected. This is the development of drugs for the treatment of small cell carcinoma (SCLC). SCLC was first discovered about 100 years ago, but it was not until 1968 that the medical community discovered its neuroendocrine origin and finally clearly distinguished it from other lung cancers. In the 1980s, the treatment of platinum-containing chemotherapy combined with chest radiotherapy gradually became clear and became the basic treatment for small cell lung cancer. Although the combination of etoposide and carboplatin/cisplatin (EP) has been the standard treatment for SCLC until now; but we can also clearly see that the battle against small cell lung cancer has entered an accelerated stage. In May of this year, Amgen’s DLL3/CD3 dual antibody Tarlatamab ...
- Source: drugdu
- 44
- November 1, 2024
Medtronic announces a Chief Medical Officer from Cleveland Medical Center

On October 28, 2024, Medtronic announced the appointment of Dr. Matthew Kroh as Chief Medical Officer for Advanced and General Surgery Technologies. Dr. Matthew Crowe is the Vice President of Innovation and Technology at the Cleveland Clinic Digestive Disease and Surgery Institute. He is the director of the Department of General Surgery, Endoscopic Surgery, and Foreintestinal Surgery. 01. Surgical Laparoscopic Specialist at Cleveland Medical Center Cleveland Clinic is one of the world’s most renowned medical institutions, founded on February 28, 1921. In the 2017-2018 ranking of the best hospitals in the United States, Cleveland Clinic ranked second overall, only behind Mayo Clinic. Among them, cardiac surgery and urology are ranked first in the United States; General surgery, rheumatology, and nephrology rank second. Dr. Matthew Crowe is from Cleveland Medical Center. According to the official website of the Cleveland Clinic, Dr. Matthew Crowe is the Vice President of Innovation and Technology ...
- Source: drugdu
- 47
- October 31, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.